Aspirin inhibits platelet aggregation by blocking the enzymatic conversion of arachidonic acid to aggregation-stimulating substances.
Answers are grounded in this paper and cite their sources.
Elucidates aspirin's antiplatelet mechanism; extends antithrombotic observations but remains hypothesis-generating for clinical use.
Aspirin-type drugs may inhibit irreversible clumping of human blood platelets by blocking the enzymatic conversion of arachidonic acid to a hitherto undiscovered factor, labile aggregation-stimulating substance, which triggers aggregation and to prostaglandin E(2), which sensitizes the platelets to its aggregatory effects.
No takes yet. Share an insight, caveat, or question.
A.L. Willis (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: